Metastatic clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer that has spread beyond the kidney, accounting for roughly three-quarters of all renal cell carcinoma cases. What makes it distinctive at the molecular level is a near-universal disruption to a single gene called VHL, which sets off a cascade of abnormal signaling that fuels tumor growth and, eventually, spread to distant organs. The treatment landscape has shifted dramatically in the past decade, with immunotherapy-based combinations now replacing the older single-drug targeted therapies as standard first-line options, and newer drugs designed to hit the VHL pathway directly entering the clinic.
The Molecular Engine Behind Clear Cell RCC
The defining event in most clear cell kidney tumors is the loss or silencing of the VHL gene. Under normal circumstances, the protein made by VHL acts as a quality-control system: it tags a molecule called HIF-alpha for destruction when oxygen levels in the cell are adequate. When VHL is knocked out, HIF-alpha accumulates even though the cell has plenty of oxygen, tricking it into behaving as though it is starved for air. The cell responds by ramping up production of proteins that promote new blood vessel growth (like VEGF and PDGF) and other survival signals.1PubMed Central. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy This explains the characteristic appearance of clear cell tumors under the microscope: they are packed with tiny blood vessels and filled with lipid and glycogen, giving the cells their “clear” look.
Among the HIF subunits, HIF-2α appears to be the main driver of tumor progression. HIF-1α, somewhat counterintuitively, seems to function more like a brake on cancer growth and is frequently deleted in advanced clear cell tumors.2PubMed Central. The VHL/HIF axis in clear cell renal carcinoma That distinction matters because it has guided drug development: the newest targeted therapy for this cancer, belzutifan, was specifically designed to block HIF-2α.
Where Metastatic ccRCC Typically Spreads
Clear cell kidney cancer has a broad and somewhat unpredictable pattern of spread. An analysis from the International Metastatic RCC Database Consortium (IMDC) found the lungs are the most frequent destination, involved in about seven out of ten patients. Lymph nodes come next at roughly half of patients, followed by bone in about a third and liver in about a fifth. Less common sites include the adrenal glands and brain, each in about one in ten patients, and the pancreas in a smaller fraction.3Journal of Clinical Oncology. Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)
One quirk that sets kidney cancer apart from many other solid tumors is its tendency to metastasize to unusual organs and to do so on a delayed timeline. Pancreatic metastases, for example, tend to grow silently and can appear decades after the original kidney tumor was removed. Case reports document recurrences as long as thirty years after the initial surgery.4PubMed Central. Late-Onset Pancreatic Metastasis From Renal Cell Carcinoma Mimicking a Neuroendocrine Tumor: A Diagnostic Challenge and Literature Review This is why follow-up imaging after kidney cancer surgery sometimes continues far longer than for other cancers, and why a new mass discovered years later in a seemingly unrelated organ still warrants investigation for possible kidney cancer recurrence.
How Doctors Gauge Prognosis
When someone is diagnosed with metastatic ccRCC, one of the first things the oncology team does is assign a risk category using a scoring system. The IMDC model is considered the gold standard for this purpose.5PubMed Central. Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors It evaluates six factors drawn from routine blood tests and clinical assessment: low red blood cell count, high platelet count, high white blood cell count, elevated calcium, reduced physical performance status, and a short interval between diagnosis and the need for treatment. Each factor present adds a point, and patients fall into three buckets:
- Favorable risk: zero factors present. Median overall survival in one large study was about 35 months after initial targeted therapy.
- Intermediate risk: one or two factors. Median survival around 17 months.
- Poor risk: three or more factors. Median survival around 5 months.6PubMed. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study
These survival figures were generated in the era of older targeted therapies; outcomes with current immunotherapy combinations are better. Still, IMDC risk group remains the primary factor that guides which treatment regimen an oncologist recommends. The intermediate-risk group is the largest, encompassing roughly half of all patients at diagnosis, and it is also the most heterogeneous since someone with one risk factor can behave quite differently from someone with two.7PubMed Central. Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma
Immunotherapy-Based Combinations as First-Line Treatment
The treatment of metastatic ccRCC was transformed by two landmark trials that paired immune checkpoint inhibitors with either another checkpoint drug or a targeted pill. In the CheckMate 214 trial, the combination of nivolumab plus ipilimumab (two immunotherapy drugs) was compared against sunitinib, which had been the standard for years. Among patients with intermediate or poor risk, the combination more than doubled the complete response rate and substantially reduced the risk of death. With eight years of follow-up, median overall survival was roughly 53 months with nivolumab-ipilimumab versus 38 months with sunitinib across the full trial population, and about 35% of patients on the combination were still alive at seven and a half years compared with about 25% on sunitinib.8Annals of Oncology. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
The KEYNOTE-426 trial took a different approach, pairing the checkpoint inhibitor pembrolizumab with the targeted drug axitinib. This combination showed benefits across all IMDC risk groups, including favorable-risk patients where the pure immunotherapy doublet was less clearly superior. After roughly a year of follow-up, about 90% of patients on pembrolizumab-axitinib were alive compared with 78% on sunitinib, and the response rate was nearly 60% versus 36%.9PubMed. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Five-year follow-up data continued to support this combination as a standard of care for advanced ccRCC.10Journal of Clinical Oncology. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426
The choice between these regimens, and others including nivolumab-cabozantinib and lenvatinib-pembrolizumab, depends partly on the IMDC risk group and partly on the patient’s overall fitness and tolerance for side effects. Real-world comparisons suggest that the immunotherapy-plus-targeted-drug combinations may produce longer time before disease worsens compared with the pure immunotherapy doublet, though head-to-head randomized data between the regimens are still lacking.11The Oncologist. Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
The Role of Surgery When Cancer Has Already Spread
Removing the primary kidney tumor in someone whose cancer has already metastasized, called cytoreductive nephrectomy, was once considered almost automatic. Two randomized trials (CARMENA and SURTIME) complicated that picture by showing that not every patient benefits from upfront surgery, and that some do better starting with systemic therapy first.12PubMed Central. Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma A systematic review and meta-analysis confirmed that cytoreductive nephrectomy is still associated with better survival overall, but the key question is timing and patient selection. Starting immunotherapy first and considering surgery later if the disease responds well appears to produce similar outcomes to operating right away.13PubMed Central. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis
For patients with only a few metastatic spots, an approach called metastasis-directed therapy is gaining traction. This can mean surgically removing individual metastases (metastasectomy) or using highly focused radiation like stereotactic body radiotherapy (SBRT). A study comparing the two approaches found median overall survival of about 51 months without a significant difference between surgery and stereotactic radiation, even though patients receiving radiation tended to have worse baseline risk profiles.14Radiotherapy and Oncology. Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005–2014 When only a handful of lesions are present and they can all be targeted, this approach can sometimes achieve long-term disease control or even cure.15PubMed Central. The Diagnosis and Treatment Approach for Oligo-Recurrent and Oligo-Progressive Renal Cell Carcinoma
HIF-2α Inhibitors and Other Targeted Drugs
Because the VHL-HIF pathway is so central to clear cell kidney cancer, researchers spent years trying to develop a drug that directly blocks HIF-2α. The result was belzutifan, which prevents HIF-2α from pairing with its partner protein and switching on the genes that drive tumor growth.16PubMed Central. Belzutifan for the treatment of renal cell carcinoma In its first-in-human trial, belzutifan produced a response in one quarter of heavily pre-treated patients with ccRCC, with a median time before the cancer worsened of about 14 and a half months. Side effects were generally manageable.17Nature Medicine. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis Belzutifan has since gained FDA approval for patients with VHL syndrome as well as for use in combination with other agents in advanced sporadic ccRCC.18PubMed Central. Targeting HIF-2α in renal cell carcinoma: Expanding upon belzutifan
Another important drug is cabozantinib, a pill that blocks not only VEGF receptors (the blood-vessel-growth pathway) but also MET and AXL, two molecules that are implicated in how tumors develop resistance to standard anti-angiogenic drugs.19PubMed Central. Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma In a pivotal trial comparing cabozantinib with the older drug everolimus in patients who had already progressed on prior therapy, cabozantinib extended both progression-free survival and overall survival.20PubMed Central. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma Cabozantinib is now used both as part of first-line immunotherapy combinations and as a later-line option on its own.
Why Treatments Eventually Stop Working
Despite the progress with immunotherapy combinations and targeted drugs, resistance remains a major challenge. Roughly 70% of patients who initially respond to anti-angiogenic drugs like sunitinib eventually develop resistance, and about 30% never respond at all. One key mechanism is the tumor’s ability to activate alternative pathways for blood vessel formation when the primary VEGF pathway is blocked.21PubMed Central. Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma
Resistance to immunotherapy is less well understood but appears to involve changes in the tumor’s local environment that suppress immune cell activity, as well as shifts in the mixture of immune cells surrounding the tumor. Tumors that are rich in certain regulatory immune cells can effectively shut down the anti-tumor response even when checkpoint inhibitors are on board.22PubMed Central. Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma The tight relationship between blood-vessel signaling and immune suppression in the tumor microenvironment is one reason the current combinations pair an immune drug with an anti-angiogenic agent: each theoretically helps the other work better.
Sarcomatoid Features and Their Surprising Implications
A small but important subset of clear cell tumors develops sarcomatoid or rhabdoid features, meaning part of the tumor takes on a spindled, aggressive-looking appearance under the microscope. Historically, sarcomatoid differentiation was considered an extremely bad sign, associated with rapid progression and poor survival. That reputation was deserved in the era of targeted therapies, but immunotherapy has partly rewritten the story.
Sarcomatoid ccRCC tumors tend to have an inflamed immune microenvironment with high levels of PD-L1 expression and strong cytotoxic immune cell infiltration, making them particularly susceptible to checkpoint blockade.23Nature Communications. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma In practice, patients with sarcomatoid clear cell RCC treated with immune checkpoint inhibitors had a response rate of about 39% and median overall survival of roughly 30 months, dramatically better than their counterparts with sarcomatoid non-clear-cell histologies who had a median survival of less than 7 months.24Urologic Oncology: Seminars and Original Investigations. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors The takeaway for patients: sarcomatoid features on a biopsy report are worrying, but they may actually predict a strong response to immunotherapy in the clear cell context.
Genomic Mutations Beyond VHL
While VHL loss is the initiating event in most ccRCC, several other genes on the same chromosome arm (3p) are frequently mutated and shape how the cancer behaves. The most commonly altered of these is PBRM1, lost in roughly 40% of tumors. PBRM1 mutations are generally associated with a more indolent disease course and possible sensitivity to anti-angiogenic drugs.25PubMed Central. Emerging roles for the epigenetic modifiers PBRM1 SETD2 and BAP1 in clear cell renal cell carcinoma pathogenesis and prognosis beyond VHL
BAP1, mutated in 10 to 15% of ccRCC tumors, paints a starkly different picture. BAP1 mutations are linked to higher-grade tumors, sarcomatoid differentiation, and worse survival.26European Urology. Clinical and Pathologic Impact of Select Chromatin-modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma SETD2 mutations, found in a similar fraction, cause genomic instability and are associated with aggressive features but may improve responsiveness to immunotherapy.27PubMed. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies The research community increasingly views these mutations as emerging biomarkers that may help guide treatment decisions, though they are not yet routinely used to choose first-line therapy in most clinical settings.
Adding another layer of complexity, clear cell tumors can vary considerably within a single patient. The TRACERx Renal study mapped molecular diversity across multiple regions of individual tumors and found that transcriptional heterogeneity varied more than tenfold from one patient to another, driven partly by subclonal genetic changes that create distinct populations of cancer cells within the same mass.28PubMed Central. Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal This internal diversity helps explain why a single biopsy may not capture the full biology of the tumor and why resistance can emerge from a pre-existing pocket of cells with different molecular characteristics.
Liquid Biopsy and Circulating Tumor DNA
One of the practical frustrations with kidney cancer is that tumors are not always easy to biopsy, especially metastatic sites in places like bone or brain. Liquid biopsy, which analyzes fragments of tumor DNA circulating in the blood (ctDNA), offers a potential alternative. A study tracking ctDNA over time in patients with metastatic RCC found high agreement between ctDNA levels and subsequent clinical outcomes: patients whose circulating tumor DNA dropped tended to respond to treatment, while rising levels predicted progression.29PubMed Central. Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma
Early data in patients starting immunotherapy with nivolumab-ipilimumab have been encouraging: ctDNA levels decreased after treatment in patients who responded and increased in a patient whose disease progressed.30Scientific Reports. Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma The limitations are real, however. Kidney cancer tends to shed less DNA into the bloodstream than many other solid tumors, so a negative ctDNA result does not reliably rule out active disease. For now, a positive ctDNA finding is more informative than a negative one, and the technology works best as an adjunct to imaging rather than a replacement.31Med. Utility of circulating tumor DNA in management of diverse renal malignancies: Insights from a case series in adjuvant and recurrent/metastatic settings
How Gut Bacteria May Influence Treatment Response
An unexpected area of research in metastatic ccRCC involves the gut microbiome. Several studies have found that the mix of bacteria in a patient’s gut correlates with how well immunotherapy works. In one cohort, greater microbial diversity in stool samples before starting checkpoint inhibitors was associated with better clinical outcomes, and specific bacterial species like Akkermansia muciniphila were more abundant in patients who benefited from treatment.32European Urology. Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti–PD-1 Immune Checkpoint Inhibitors
The flip side is also relevant: antibiotic use around the time of immunotherapy initiation appears harmful. In one study, patients who had recently taken antibiotics had response rates drop from 28% to 9%, and their stool showed an overgrowth of species linked to poorer outcomes.33European Urology. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients Broad-spectrum antibiotics were associated with worse progression-free survival and dramatically higher rates of disease that never responded to immunotherapy at all.34PubMed Central. Gut microbiota and immunotherapy of renal cell carcinoma This does not mean patients should refuse necessary antibiotics, but it has prompted some oncology teams to be more judicious about prescribing them around the start of immunotherapy and has spurred trials investigating whether probiotics or other microbiome-modifying strategies could improve treatment outcomes.
Quality of Life on Treatment
Living with metastatic ccRCC and its treatments can take a toll that goes beyond tumor measurements. The shift from older single-agent targeted drugs to newer immunotherapy combinations has had meaningful quality-of-life implications. In the CheckMate 025 trial comparing nivolumab with everolimus in previously treated patients, more than half of those on nivolumab reported a clinically meaningful improvement in quality of life, compared with roughly a third on everolimus, and the improvement came sooner.35The Lancet Oncology. Health-related quality of life and symptom burden in patients with advanced renal cell carcinoma treated with nivolumab versus everolimus (CheckMate 025)
A review of patient-reported outcomes across six first-line combination trials found that two regimens consistently outperformed sunitinib on quality-of-life measures: nivolumab plus cabozantinib, and atezolizumab plus bevacizumab. Nivolumab-ipilimumab and lenvatinib-pembrolizumab also generally outperformed the older drug, though some trials had design limitations that may have masked benefits in quality-of-life reporting.36Nature Reviews Urology. Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment For patients weighing the trade-offs of different regimens, the message is that newer combinations are not just better at shrinking tumors; for many people, they also feel better to be on.
CAR-T Cells and Other Early-Stage Approaches
Chimeric antigen receptor (CAR) T-cell therapy, which has transformed the treatment of certain blood cancers, is being explored in kidney cancer as well, though the results so far are modest. Early attempts targeting a protein called CAIX, which is overexpressed in ccRCC, ran into liver toxicity and produced no clinical responses. A separate trial targeting VEGF was stopped early for futility. The most promising lead involves CD70, a molecule highly expressed on clear cell tumors. In the phase 1 COBALT-RCC study, an engineered CAR-T product targeting CD70 achieved disease control in about 80% of 16 patients with relapsed metastatic ccRCC, including one patient who achieved a complete response lasting at least three years.37The Oncologist. Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma That single durable complete response was a first for CAR-T therapy in any form of kidney cancer. Clinical development continues, but CAR-T for solid tumors remains in its early chapters.
On the imaging front, researchers are developing PET tracers that target molecules specific to ccRCC. One tracer targeting CD70 outperformed standard FDG-PET at identifying ccRCC metastases,38Journal of Nuclear Medicine. CD70-Targeted Immuno-PET/CT Imaging of Clear Cell Renal Cell Carcinoma: A Translational Study and a PSMA-targeted tracer detected more metastatic sites than conventional imaging in a small series of patients.39PubMed Central. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT If validated in larger studies, these tracers could improve staging accuracy and potentially help match patients to therapies that target the same molecules the tracers light up.